The IL-1 Alpha Locus: Inflammation at the Root of Endometriosis
Endometriosis — where endometrial-like tissue grows outside the uterus — affects an
estimated 10% of reproductive-age women and is driven as much by immune dysfunction
as by hormonal disruption. This variant sits within a dense inflammatory gene cluster
on chromosome 2q13 that encodes six members of the
interleukin-1 family11 interleukin-1 family
IL-1 is a family of pro-inflammatory cytokines that coordinate
immune responses and tissue remodelling,
including IL-1 alpha (IL1A) and IL-1 beta (IL1B). Genetic variation here has been
consistently linked to endometriosis risk across diverse populations.
The Mechanism
The rs10167914 variant does not change an amino acid; it sits in the regulatory landscape
surrounding IL1A and IL1B and influences how much IL-1 alpha the body produces in
peritoneal tissue. The G allele is associated with higher local IL-1 alpha expression.
IL-1 alpha, in turn, directly stimulates matrix metalloproteinase-1 (MMP-1)22 matrix metalloproteinase-1 (MMP-1)
an enzyme
that breaks down the extracellular matrix, enabling ectopic cells to invade surrounding
tissue, recruits inflammatory cells to the
peritoneum, and sustains the chronic low-grade inflammation that allows endometriotic
implants to establish, survive, and proliferate. G-allele carriers thus have a molecular
environment more permissive to lesion growth — not through oestrogen alone, but through
an IL-1-mediated inflammatory loop.
The Evidence
The strongest signal comes from a large
meta-analysis by Sapkota et al.33 meta-analysis by Sapkota et al.
Sapkota Y et al. Meta-analysis identifies five novel
loci associated with endometriosis highlighting key genes involved in hormone metabolism.
Nat Commun, 2017 combining 17,045 endometriosis
cases with 191,596 controls. rs10167914-G reached p=1×10⁻⁹ with an odds ratio of 1.12
(95% CI 1.08–1.15), a replicable, genome-wide-significant effect. An earlier targeted study
Sapkota et al. 201544 Sapkota et al. 2015
Sapkota Y et al. Association between endometriosis and the
interleukin 1A (IL1A) locus. Hum Reprod, 2015
confirmed IL1A locus signals in both European and Japanese samples, with
rs6542095 reaching OR 1.21 for moderate-to-severe disease.
A detailed functional analysis by
Gajbhiye et al. 201855 Gajbhiye et al. 2018
Gajbhiye R et al. Genetic Variation at Chromosome 2q13 and Its
Potential Influence on Endometriosis Susceptibility Through Effects on the IL-1 Family.
Reprod Sci, 2018 mapped the 500 kb region
around rs10167914 and found that the locus spans 21 transcripts including six IL-1 family
genes, supporting a regulatory role whereby risk variants alter expression across this
entire cytokine network rather than affecting a single gene.
Protein-level confirmation comes from
Hudelist et al. 200566 Hudelist et al. 2005
Hudelist G et al. Interleukin 1alpha and tissue-lytic MMP-1 are
elevated in ectopic endometrium. Hum Reprod, 2005:
IL-1 alpha staining was significantly higher in endometriotic lesions than in matched
eutopic endometrium (p<0.001), with co-expression of MMP-1, the matrix-degrading enzyme
it induces.
Practical Actions
For women carrying one or two G alleles, the actionable terrain involves managing IL-1 pathway activity and reducing the peritoneal inflammatory load. Long-chain omega-3 fatty acids (EPA and DHA) downregulate IL-1 alpha production by shifting eicosanoid biosynthesis toward less pro-inflammatory prostaglandins. This is a mechanism-specific intervention, not generic anti-inflammatory advice — the same shift does not occur with short-chain ALA from plant oils.
In clinical settings, IL-1 receptor antagonism (anakinra, canakinumab) is being explored for endometriosis. Women with confirmed or suspected endometriosis who carry the G allele have a biological rationale to discuss IL-1 pathway modulation with a specialist, particularly if standard hormonal therapies have been inadequate.
Interactions
The IL1A locus does not operate in isolation. IL-1 alpha signalling amplifies oestrogen- driven lesion survival — rs10167914-G carriers who also carry variants reducing oestrogen catabolism (e.g. CYP1B1 or CYP19A1 variants) may face a compounded inflammatory-hormonal milieu. Similarly, variants affecting NF-κB activation (TNF-α locus, NFKB1) or the prostaglandin pathway (PTGS2/COX-2) share mechanistic overlap with IL-1 signalling in endometriotic tissue. No compound action is proposed here — these interactions require dedicated literature support rather than pathway inference alone.